

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT
APPLICATION

Inventor(s): HANSEN et al.

Appln. No.: 08

Series Code ↑

491,892

Serial No. ↑

Group Art Unit

1209

Examiner:

Badio

Atty. Dkt.

218100

RY/JKM/551

M#

Client Ref

Filed: July 14, 1995

Title: NEW CRYSTALLINE FORM OF A VITAMIN D ANALOGUE

(Our Deposit Account No. 03-3975)

(Our Order No.

41632

218100

C#

M#

Date:


January 9, 1997

Hon. Commissioner of Patents

and Trademarks

Washington, D.C. 20231

Sir:



RESPONSE/AMENDMENT/LETTER

This is a response/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. "Small Entity" statement(s) filed

- ☐ previously
☐ herewith

(No.)

	Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity.	Additional Fee	Fee Code
2. Total Effective Claims	8	**minus 20	0	x \$22/\$11 =	+ 0	103/203
3. Independent Claims	3	***minus 3	0	x \$80/\$40 =	+ 0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application)..... add				+ \$260/\$130 =	+ 0	104/204
5. Original due Date: January 9, 1997	<input type="checkbox"/> NONE					
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached		(1 mo) (2 mos) (3 mos)	\$110/\$55 = \$390/\$195 = \$930/\$465 =	+ 0		115/215 116/216 117/217
7. Enter any previous extension fee paid since above original due date and subtract			-			
8.	Extension Fee Attached				+ 0	
9. If Terminal Disclaimer attached, add Rule 20(d) official fee				+ \$110/\$55 =	+ 0	148/248
10. If IDS attached requires Official Fee, add				+ \$230 =	+ 0	126
or if Rule 97(d) Petition add				+ \$130 =		122
11. After-Final Request Fee per rules 129(a) and 17(r)				+ \$750/375 =	+ 0	146/246
12. No. of additional inventions for examination per Rule 129(b)				x \$750/375 ea =	+ 0	149/249
13. Petition fee for					+	
14.	TOTAL FEE ENCLOSED =				\$0	

15. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

16. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

17. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown in the heading hereof, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Cushman Darby & Cushman
Intellectual Property Group of
Pillsbury Madison & Sutro LLP

By: Atty: Paul N. Kokulis

Reg. No. 16773

1100 New York Avenue, N.W.

Ninth Floor East Tower

Washington, D.C. 20005-3918

Tel: (202) 861-3000

PNK/lap

Sig:

Fax:

(202) 822-0944

Tel:

(202) 861-3503

NOTE: File this cover sheet in duplicate with PTO receipt (CDC-103A) and attachments

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re PATENT APPLICATION

HANSEN et al.

Appln. No.: 08/491,892

Filed: July 14, 1995

FOR: NEW CRYSTALLINE FORM OF A VITAMIN D ANALOGUE



Group Art Unit: 1205

Examiner: Badio

Handwritten: 5/a
2/1/97

* * * * *

January 9, 1997

AMENDMENT

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

Sir:

In response to the Office Action of October 9, 1996, kindly enter the following amendments and remarks.

IN THE CLAIMS:

Claim 1, line 1, delete "2" and the accompanying footnote.

Claim 5, lines 1-2, delete "any one of claims 2-4" and insert --claim 4--.

Kindly add the following new claims:

--6. Calcipotriol monohydrate according to claim 1, said monohydrate being characterized by its storage stability at 40°C, its ready wettability and wet ball milling characteristics.

7. The method of preparing calcipotriol monohydrate which comprises dissolving calcipotriol in organic solvent and then adding water to the resulting solution to precipitate the hydrate.

Handwritten: 6/1
B2